Product Images Levothyroxine Sodium

Levothyroxine Sodium Tablets, USP manufactured by Ascent Pharmaceuticals, Inc. This medication comes in a bottle with 1000 tablets and is only available with a prescription. Each tablet contains 100 meg of Levothyroxine sodium, USP. The medication should be kept in a tightly sealed, light-resistant container to protect it from moisture and light at controlled room temperature, with permitted temperature excursions between 15° and 30°C (59° and 86°F). Administration and dosage of this medication require a doctor's prescription.*

This is a description of Sodium Tablets containing Levothyroxine. Each tablet contains 112 micrograms (0.112mg) of Levothyroxine sodium, USP. The NDC number is 43602-422-10 and the package contains 1000 tablets, which are available by prescription only. The prescribing information should be consulted for dosage and administration instructions. The tablets should be stored in a tight, light-resistant container at controlled room temperature between 20°C and 25°C (68°F and 77°F), with excursions between 15°C and 30°C (59°F and 86°F) allowed. Moisture and light should be avoided. The manufacturer is Ascent Pharmaceuticals, Tnc. located in Central Islip, NY 11722.*

This is a description of a medication for Levothyroxine sodium tablets. The tablets come in a container of 1000 tablets, with each tablet containing 125 meg of the medication. The tablets are only available with a prescription, and full prescribing information concerning dosage and administration is included. Retailers should dispense the tablets in a tightly sealed, light-resistant container, and store them in a temperature-controlled environment within the ranges of 20° - 25°C (68° - 77°F), with excursions allowed between 15° and 30°C (59° and 86°F). The medication should be protected from both light and moisture. Ascent Pharmaceuticals based in Central Islip, NY 11722, manufacture this medication.*

Each tablet contains Levothyroxine sodium, USP 137 mcg. This is a prescription medication that needs to be stored at controlled room temperature. Protect from moisture and light. Manufactured by Romly of Pharmaceuticals Inc. Contains 1000 tablets. Rev 12/20.*

NDC 43602-425-10 is a medication container with tablets that contain Levothyroxine sodium, USP 150 mcg. The container should be stored at a controlled room temperature with excursions allowed between 15° and 30°C (59° and 86°F). The sodium tablets should be protected from moisture and light. The manufacturer is located in Central Islip, NY 11722.*

This is a description for medication with the NDC 43602-426-10 code. The medication is Levothyroxine sodium, USP 175 mcg in the form of tablets. The tablets should be stored at a controlled room temperature between 20° - 25°C (68° - 77°F), with excursions allowed between 15° and 30°C (59° and 86°F). The medication should always be protected from moisture and light. The manufacturer of the medication is listed as Romly ot Phammacowicals Tnc and 1000 tablets are included in the package.*

This is a description of Levothyroxine Sodium tablets. The tablets come in a pack of 1000 and are only available on prescription. Each tablet contains 200 mcg of Levothyroxine Sodium. The tablets should be stored in a tightly sealed container at a controlled room temperature between 20°C - 25°C. These tablets are manufactured by Ascent Pharmaceuticals, located in Central Islip, NY 11722.*

Levothyroxine Sodium Tablets USP 25 meg (0.025 mg) is a prescription medication dispensed in a light-resistant container. Each bottle contains 1000 tablets of Levothyroxine sodium, which is an active ingredient. The medication is used to treat an underactive thyroid gland by regulating the body's metabolism. The patient should read the prescription guidelines before administering the drug, including dosage and administration instructions. The manufacturer is Ascent Pharmaceuticals, Inc., located in Central Islip, NY. It should be stored at room temperature in a dry, moisture-free environment.*

This is a description of a medication with the National Drug Code (NDC) of 43602-428-10. The medication is a tablet that contains 300 mcg of Levothyroxine sodium, which is used for hormone replacement therapy in patients with an underactive thyroid gland. The instructions indicate that the medication should be stored at a controlled room temperature (68°F-77°F) and protected from moisture and light. The medication is manufactured by Romley Pharmaceuticals, and each bottle contains 1000 tablets.*

Levothyroxine Sodium Tablets, USP of 50mg strength with NDC number 43602-418-10 is available in a container of 1000 tablets. It is a prescription medicine containing Levothyroxine sodium, USP. The prescribing information provides details of dosage and administration. The tablets should be stored in a tightly closed light-resistant container at a controlled room temperature of 20° - 25°C (68° - 77°F) with excursions allowed between 15° and 30°C (59° and 86°F). Moisture and light should be avoided while storing. This medicine is manufactured by Ascent Pharmaceuticals, Tnc. at Central Islip, NY 11722.*

Each tablet of this medication, identified by the NDC code 43602-419-10, contains 75 micrograms of Levothyroxine sodium, which is an artificial hormone used to treat an underactive thyroid gland. The medication should be stored at room temperature between 20° and 25°C (68° and 77°F), with brief excursions between 15° and 30°C (59° and 86°F) permitted. Protection from light and moisture is also recommended. The medication comes in a bottle containing 1000 tablets and is manufactured by a company located in Central Islip, NY.*

This is a description of a medication called Levothyroxine Sodium Tablets. It comes in a bottle of 1000 tablets and each tablet contains 88 mcg of Levothyroxine sodium. This medicine requires a prescription for purchase and must be kept in a tight, light-resistant container at a controlled room temperature. It is manufactured by Ascent Pharmaceuticals in Central Islip, NY.*

This text provides a dosing guideline for children with hypothyroidism using Levothyroxine Sodium tablets. The guideline is based on the child's age and body weight, with daily doses ranging from 10-15 micrograms/kg/day for infants up to 3 months old to 1.6 micrograms/kg/day for adolescents who have completed growth and puberty. The dose should be adjusted based on clinical response and laboratory parameters.*

This is a table containing information regarding drugs that may decrease T4 absorption and impact the efficacy of levothyroxine sodium tablets, potentially leading to hypothyroidism. It lists various drugs and drug classes that are likely to form insoluble chelates or complexes, causing delay or prevention of absorption of levothyroxine. Administering levothyroxine sodium tablets at least 4 hours apart from these agents is recommended. Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption, and thus, administering levothyroxine sodium tablets at least 4 hours prior to these drugs or monitoring TSH levels is advised. Gastric acidity is a requisite for adequate absorption of levothyroxine, making Sucralfate, antacids, and proton-pump inhibitors harmful since they may cause hypochlorhydria, affect intragastric pH, and consequently reduce levothyroxine absorption. Appropriate monitoring of patients is suggested in these cases.*

The text describes a table of drugs that may affect the transport of T4 and T3 in the body without affecting FT4 concentration. The table has two sets of drugs with opposite effects on the serum thyroxine-binding globulin concentration. The potential impact of these drugs when administered with levothyroxine is also mentioned. Salicylates are discussed separately from the other drugs because they inhibit the binding of T4 and T3 to TBG and transthyretin. Finally, the text mentions other drugs like carbamazepine and NSAIDs that may cause protein-binding site displacement, which could reduce the total and free levels of T4 by 20% to 40% while mostly keeping TSH levels normal.*

This is a table listing drugs that may impact the metabolism of levothyroxine in patients with hypothyroidism. It explains that drugs like Phenobarbital and Rifampin may stimulate hepatic enzyme activity leading to increased degradation of levothyroxine, resulting in higher requirements of levothyroxine sodium tablets. This information is useful for doctors who prescribe medication for hypothyroidism and need to consider the effects of other drugs on the metabolism of levothyroxine in their patients.*

This text describes a table with drugs that may impact the conversion of T4 to T3, leading to decreased T3 levels, but usually normal T4 levels. Beta-adrenergic antagonists like propranolol and short-term administration of high doses of glucocorticoids like Dexamethasone are among the drugs listed. Long-term use of glucocorticoids may affect TBG production. Furthermore, Amiodarone may cause biochemical changes in clinically euthyroid patients.*

The text is a table providing information about different colored additives used in Levothyroxine Sodium Tablets of varying strengths, ranging from 100 to 125 meg. The table includes the strength of the tablet, the color additives used, and the type of color additives incorporated, such as FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2, and D & C Yellow No. 10.*

Table 7 provides pharmacokinetic parameters of thyroid hormones in euthyroid patients. The table includes information about the biological potency, half-life, and protein binding percentages of two types of thyroid hormones: levothyroxine (T4) and liothyronine (T3). The table also specifies that the half-life of T4 is 1-2 days and its protein binding percentage is 99.96, whereas the T3 hormone has a potency ratio of 2:1 with T4 and its half-life is not specified. There is also additional information about the protein ratio in serum and the duration of the half-life in hyperthyroidism and hypothyroidism states.*